Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Anika Therapeutics (ANIK) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 731,590
  • Shares Outstanding, K 14,780
  • Annual Sales, $ 93,000 K
  • Annual Income, $ 30,760 K
  • 36-Month Beta 1.75
  • Price/Sales 6.93
  • Price/Book 3.45

Price Performance

See More
Period Period Low Period High Performance
47.73 +5.05%
on 12/19/16
51.15 -1.97%
on 01/10/17
+1.09 (+2.22%)
since 12/16/16
41.38 +21.17%
on 11/03/16
51.15 -1.97%
on 01/10/17
+5.17 (+11.50%)
since 10/18/16
35.07 +42.97%
on 01/28/16
54.96 -8.77%
on 07/05/16
+12.04 (+31.60%)
since 01/15/16

Most Recent Stories

More News
Allergan's Uterine Fibroids Candidate Positive in Phase III

Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding...

Concert Offers Update on Cystic Fibrosis Drug, Stock Down

Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.

Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of...

Jazz Begins Phase III Study for Label Expansion of Defitelio

Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease....

AstraZeneca Offers Update on Immuno-Oncology Program

AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

Kura Oncology Starts Dosing Patients in Phase II CMML Study

Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.

Benitec Stock Up on Orphan Drug Status for BB-301 in EU

Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to...

See More

Support & Resistance

2nd Resistance Point 50.71
1st Resistance Point 50.42
Last Price 50.14
1st Support Level 49.88
2nd Support Level 49.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.